Karen Kelly

Also affiliated with Colorado Women's College, Naval Health Research Center, Sidney Kimmel Cancer Center, International Association for the Study of Lung Cancer, UC Davis Comprehensive Cancer Center, University of California, Davis, Stanford University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.9Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 50 papers — median percentile 0. Top paper: “Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer”.

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209

N/A

3.1DataRank · unranked

105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013

N/A

2.3DataRank · unranked

79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3947

N/A

0.862DataRank · unranked

21 citations

Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner +10 more

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.10.002

N/A

0.659DataRank · unranked

13 citations

Mary W. Redman, James Moon, Francesco Agustoni, Roy S. Herbst, Thomas J. Semrad +6 more

Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo

Nucleic Acids Research(2023)10.1093/nar/gkad1125

N/A

0.563DataRank · unranked

17 citations

Karen Kelly, Jonathan Lee, Dimas Echeverria, David Cooper, Rebecca Panwala +13 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532

N/A

0.552DataRank · unranked

9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

Domain-inlaid Nme2Cas9 adenine base editors with improved activity and targeting scope

Nature Communications(2024)10.1038/s41467-024-45763-5

N/A

0.517DataRank · unranked

15 citations

Han Zhang, Xiaolong Dong, Haoyang Cheng, Nicholas Gaston, Hailey Feinzig +7 more

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.07.024

N/A

0.326DataRank · unranked

5 citations

Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev +10 more

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9075

N/A

0DataRank · unranked

1 citations

Mary W. Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi +7 more

Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector

GEN Biotechnology(2022)10.1089/genbio.2022.0015

N/A

0DataRank · unranked

68 citations

Nathan Bamidele, Pengpeng Liu, Ogooluwa Ojelabi, Xin D. Gao, Tomás Rodríguez +9 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741

N/A

0DataRank · unranked

55 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts

Nucleic Acids Research(2022)10.1093/nar/gkac630

N/A

0DataRank · unranked

29 citations

Io Long Chan, Yuming Cao, Alisha M. Gruntman, Jonathan Lee, Jacquelyn Sousa +17 more

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100427

N/A

0DataRank · unranked

12 citations

Shuai Chen, Joanna B. Eldredge, Shiruyeh Schokrpur, Debory Li, Zhikuan Quan +11 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0029

N/A

0DataRank · unranked

1 citations

Xing Hua, Khaled Tolba, David Fabrizio, Lee A. Albacker, Ryan Brennick +11 more

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6543

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Qian Lü, Katherine Minichiello, Roy S. Herbst, David R. Gandara +14 more

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9044

N/A

0DataRank · unranked

0 citations

Hsin-Hui Huang, Mary W. Redman, Roy S. Herbst, Scott Gettinger, Lyudmila Bazhenova +15 more

Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2219523120

N/A

0DataRank · unranked

48 citations

Minwook Shin, Ching‐Wen Chang, Daniel O’Reilly, Annabelle Biscans, Ken Yamada +41 more

In Vivo Prime Editing by Lipid Nanoparticle Co-Delivery of Chemically Modified pegRNA and Prime Editor mRNA

GEN Biotechnology(2023)10.1089/genbio.2023.0045

N/A

0DataRank · unranked

33 citations

Karen Kelly, Haoyang Cheng, Xiaolong Dong, Adam K. Hedger, Li Li +3 more

The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.08.016

N/A

0DataRank · unranked

19 citations

Murry W. Wynes, Casey Connolly, Kazuto Ashizawa, Sukhinder Atkar-Khattra, Chandra P. Belani +25 more

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial

Nature Communications(2023)10.1038/s41467-023-40813-w

N/A

0DataRank · unranked

20 citations

Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina +18 more

A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors

The CRISPR Journal(2023)10.1089/crispr.2023.0048

N/A

0DataRank · unranked

7 citations

Suet‐Yan Kwan, Aamir Mir, Max D. Hazeltine, Minwook Shin, Shun‐Qing Liang +11 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003

N/A

0DataRank · unranked

8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

175P Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2899

N/A

0DataRank · unranked

1 citations

Fenghai Duan, Vidya Sankar Viswanathan, Mohammadhadi Khorrami, Ning An, Vamsidhar Velcheti +7 more

Self-delivering CRISPR RNAs for AAV Co-delivery and Genome Editing in vivo

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.20.533459

N/A

0DataRank · unranked

1 citations

Karen Kelly, Jonathan Lee, Dimas Echeverria, David Cooper, Rebecca Panwala +11 more

Data from Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma

(2023)10.1158/1940-6207.c.6544974.v1

Top 100%

0DataRank

Top 100%0 citations

Dmitry Grapov, Johannes F. Fahrmann, Brian C. DeFelice, William N. Rom, Harvey I. Pass +8 more

Engineering Nme2Cas9 Adenine Base Editors with Improved Activity and Targeting Scope

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.14.536905

N/A

0DataRank · unranked

0 citations

Han Zhang, Xiaolong Dong, Nicholas Gaston, Haoyang Cheng, Karen Kelly +5 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035

N/A

0DataRank · unranked

0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0251

N/A

0DataRank · unranked

42 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.10.021

N/A

0DataRank · unranked

32 citations

Jieling Miao, Karen L. Reckamp, Carl M. Gay, Lauren A. Byers, Ying‐Qi Zhao +15 more

Increasing intracellular dNTP levels improves prime editing efficiency

Nature Biotechnology(2024)10.1038/s41587-024-02405-x

N/A

0DataRank · unranked

29 citations

Karthikeyan Ponnienselvan, Thomas Nyalile, Sarah Oikemus, Anya T. Joynt, Sukanya Iyer +18 more

Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system

Molecular Therapy(2024)10.1016/j.ymthe.2024.10.024

N/A

0DataRank · unranked

26 citations

Julia M Rembetsy-Brown, Samantha L. Sarli, Holly R McEachern, Feng Wang, Masahiro Ohara +12 more

Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo

Nucleic Acids Research(2024)10.1093/nar/gkae260

N/A

0DataRank · unranked

18 citations

Hassan H. Fakih, Karen Kelly, Gitali Devi, Julia M Rembetsy-Brown, Holly R McEachern +8 more

State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100776

N/A

0DataRank · unranked

6 citations

Ahmed Magdy Rabea, Philip C. Mack, Janakiraman Subramanian, Ehab Khalil, Mai Sherif +27 more

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100738

N/A

0DataRank · unranked

4 citations

Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan W. Riess, Tawee Tanvetyanon +8 more

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100706

N/A

0DataRank · unranked

2 citations

Matthew S. Lara, Miguel López de Rodas, Guillaume Luxardi, Samantha Herbert, Michiko Shimoda +9 more

Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

(2024)10.1158/1078-0432.c.7181344.v1

Top 100%

0DataRank

Top 100%0 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Prophages are infrequently associated with antibiotic resistance in Pseudomonas aeruginosa clinical isolates

mSphere(2025)10.1128/msphere.00904-24

N/A

0DataRank · unranked

7 citations

Julie D. Pourtois, Naomi L. Haddock, Daisuke Furukawa, Karen Kelly, Derek F. Amanatullah +5 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7

N/A

0DataRank · unranked

125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-y

N/A

0DataRank · unranked

1 citations

Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O’Sullivan Coyne, Vincent Chung +17 more

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.10.015

N/A

0DataRank · unranked

11 citations

Mary W. Redman, Karen Kelly, S. Waqar, Francisco Robert, Gauri Kiefer +6 more

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1412

N/A

0DataRank · unranked

8 citations

Eric Laille, Ulka N. Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati +16 more

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9077

N/A

0DataRank · unranked

31 citations

Sumithra J. Mandrekar, Geoffrey R. Oxnard, David Kozono, Shauna L. Hillman, Suzanne E. Dahlberg +13 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576

N/A

0DataRank · unranked

2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623

Top 100%

0DataRank

Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001

N/A

0DataRank · unranked

32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.02.009

N/A

0DataRank · unranked

26 citations

Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker +13 more

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9024

N/A

0DataRank · unranked

10 citations

Mary W. Redman, Paul Wheatley‐Price, Bryan A. Faller, Liza C. Villaruz, Larry Corum +10 more

Karen Kelly

Indexed papers

Top data-sharing exemplar

Papers